Morgan Stanley Maintains Equal-Weight on Immunocore Holdings, Raises Price Target to $36
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Andrew Galler maintains Immunocore Holdings (NASDAQ:IMCR) with a Equal-Weight and raises the price target from $34 to $36.
Morgan Stanley analyst Andrew Galler maintains Immunocore Holdings (NASDAQ:IMCR) with a Equal-Weight and raises the price target from $34 to $36.